Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts
Summary
Tango Therapeutics has an exciting new opportunity to join the team as Sr. Manager, GXP Quality (GCP/GLP/GVP). Your primary responsibilities of this first in role position will be to ensure quality and compliance of Tango’s development programs in accordance with applicable regulatory requirements (FDA/EMA, and current industry guidance) and internal procedures, as well as to support the non-clinical team to ensure GLP studies are conducted in a compliant manner. You will report to the Director, Clinical Quality & Compliance.
Your role:
- You will provide GCP/GLP/GVP QA oversight and support to cross functional stakeholders
- Support development of the annual GCP/GLP/GVP audit schedule
- Conduct and/or oversee GCP/GLP/GVP audits through closure as per the annual audit schedule, to include clinical investigator sites, CROs/vendors, process, system, study project, and document audits, to assure compliance with global regulations, guidance, and internal procedures
- Track and effectively communicate deviation and audit trends to stakeholders
- Identify, investigate, escalate, track, and resolve quality issues both internally and externally
- Liaise with QA counterpart at CROs and vendors
- Assist in preparing for, and hosting regulatory inspections with cross functional stakeholders
- Conduct QA review of GCP protocols, ICFs, CSRs, and other clinical trial specific documents
- Conduct QA review of GLP reports and validation plans
- Additional duties and responsibilities as required
What you bring:
- Bachelor’s Degree in a scientific discipline; advanced degree preferred
- At least 7 years in the pharmaceutical industry with 5 years in GCP QA
- Solid understanding of regulations and guidance for GCP, GLP, and GVP
- Experience with US and international clinical studies
- Excellent verbal and written communication skills
- Experience reviewing clinical documents
- Good organizational skills and ability to work independently
- Collaborative problem-solver
- Able to travel domestically and internationally approximately 25% of the time
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
What We Do
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients.
Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents.
Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion.
What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity.
Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
